Perceptive Advisors-backed Arya Sciences completed the acquisition of Immatics for $252m.

Private equity firm Perceptive Advisors-backed Arya Sciences, a special purpose acquisition company, completed the acquisition of Immatics Biotechnologies, a clinical-stage biopharmaceutical company for $252m. “We greatly value the commitment from Perceptive Advisors and other top-tier investors who are participating in this transaction, as well as our existing investors who have supported the development of Immatics to date. We believe this business combination with Arya represents a unique opportunity to transition our company onto a global stage," Harpreet Singh, Immatics Co-Founder and CEO.